Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib in Nonsegmental Vitiligo
NCT07108283Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Nov 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of zasocitinib in nonsegmental vitiligo (NSV), sponsored by Takeda. Started Nov 2025; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT07108283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108283.